SummaryRMgm-5127
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 35403820 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Kehrer J, Frischknecht F |
Name Group/Department | Integrative Parasitology, Center for Infectious Diseases |
Name Institute | Heidelberg University Medical School |
City | Heidelberg |
Country | Germany |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-5127 |
Principal name | Marker free Concavin(-) NS |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not tested |
Fertilization and ookinete | Not tested |
Oocyst | Slightly reduced numbers of oocysts |
Sporozoite | We regularly found large numbers of concavin(-) sporozoites within the salivary glands, however, a large proportion of sporozoites showed an abnormal shape. While wild type sporozoites usually keep the typical curved and slender shape at any time post salivary gland entry, concavin(-) sporozoites rounded up over time. Rounding up of concavin(-) sporozoites was initiated at the posterior end of the cell and hence appeared different to the rounding observed after liver cell entry. Over 90% of oocyst-derived concavin(-) sporozoites were normally formed. Yet with prolonged residency in salivary glands more sporozoites became deformed or rounded up completely. In contrast, we never observed deformed wild type sporozoites, neither in the midgut nor in the salivary gland. Curiously, both deformed and normally shaped sporozoites were still able to move. While normally shaped concavin(-) sporozoites displayed circular movement in a wild type manner with nearly wild type speed, deformed sporozoites progressed with significantly slower speed. Deformed sporozoites also moved on less curved paths as did wild type or normally formed concavin(-) parasites. |
Liver stage | 8 of 12 mice that were bitten by concavin(-) infected mosquitoes became infected. In these 8 mice the development of the blood stage infection was delayed by over one day compared to the wild type controls (a loss of 90% infectivity). |
Additional remarks phenotype | Mutant/mutation Additional information Evidence is prsented that: Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PbANKA_1422900 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0814600 | ||||||||||||||||||||||||
Gene product | PIMMS22 protein, putative | ||||||||||||||||||||||||
Gene product: Alternative name | concavin | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | 5-fluorocytosine (5-FC) | ||||||||||||||||||||||||
Additional remarks genetic modification | The 3`UTR (779 bp) of PbANKA_1422900 was amplified from wild type gDNA using primers JK57 and JK58 and inserted into a plasmid (pL22) containing the recyclable yFCU/ hDHFR selection cassette and gfp expressed under the hsp70 promoter digested with NotI and SacII. The 5`UTR (554 bp) was amplified using primers JK55 and JK56 and inserted into the plasmid using KpnI and HindIII. The resulting plasmid pL24 was linearized with KpnI and SacII prior transfection for double crossover integration | ||||||||||||||||||||||||
Additional remarks selection procedure | The mutant does not contain thge (positive) drug selectable marker hdfr/yfcu. The selectable marker has been removed by negative selection. The drinking water of mice infected with concavin(-) parasites was supplemented with 2 mg/ml 5-FC (5-fluorocytosine). Clonal parasites which looped out the selection cassette were obtained by limiting dilution. | ||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |